My watch list  

4 Current news of Watson Pharmaceuticals


You can refine your search further. Select from the filter options on the left to narrow down your results.

Watson Completes Actavis Acquisition


Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded the ...


Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab


Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year Synthon ...


Watson Names Robert A. Stewart Senior Vice President, Global Operations


Watson Pharmaceuticals announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately. In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technical ...


Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit


Watson Pharmaceuticals, Inc. announced a license agreement with GeneraMedix, Inc. for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE